DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dynacirc CR (Isradipine) - Published Studies

 
 



Dynacirc CR Related Published Studies

Well-designed clinical trials related to Dynacirc CR (Isradipine)

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). [2013]

Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals. [2005.12]

Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. [2005.06]

Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. [2005.03]

Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. [2005.01]

Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. [2004.05.03]

Effects of isradipine on cocaine-induced subjective mood. [2004.04]

Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. [2003.07]

Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. [2003.01]

[Comparison of nicardipine and isradipine in hypertension following coronary artery bypass graft] [2002.03]

Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia. [2001.05]

A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. [2001.05]

Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. [2000.11]

Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. [2000.07.15]

Effects of enalapril and isradipine alone and in combination on blood pressure, renal function and echocardiographic parameters in mild hypertension. [2000.06.12]

Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected? [2000.04]

Long-term renal and cardiovascular effects of antihypertensive treatment regimens based upon isradipine, perindopril and thiazide. [2000]

Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced reduction in hunger. [1999.10]

Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. [1999.10]

Short-term metabolic effects of isradipine and metoprolol in pre-eclampsia. [1999.08]

Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study. [1999.06]

An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. [1999.05]

Isradipine in prediabetic hypertensive subjects. [1998.12]

Preeclampsia: haemostatic status and the short-term effects of methyldopa and isradipine therapy. [1998.06]

Effect of multiple doses of oral isradipine on atrioventricular conduction in patients with first-degree atrioventricular block. [1998.03]

Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects. [1997.12]

Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. [1997.12]

Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. [1997.11]

Antihypertensive and renal effects of isradipine in essential hypertension: focus on renin system activity. [1997.11]

Comparison of isradipine and enalapril effects on regional carotid circulation in patients with hypertension with unilateral internal carotid artery stenosis. [1997.11]

Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. [1997.07]

Effect of isradipine on in-vivo platelet function. [1997.06.01]

Isradipine for the prevention of cyclosporine-induced hpertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. [1997.04.15]

Effect of calcium channel blockade on skin blood flow in diabetic hypertension: a comparison of isradipine and atenolol. [1997.03]

Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients. [1997.01]

Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. [1996.09.11]

Sustained blood pressure control with controlled-release isradipine (isradipine-CR). [1995.03]

Sustained blood pressure control with controlled-release isradipine. [1995.01]

Well-designed clinical trials possibly related to Dynacirc CR (Isradipine)

Pharmacotherapy review of chronic pediatric hypertension. [2011.10]

Glycemia in newborns of hypertensive mothers according to maternal treatment. [2004.10]

Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. [2004]

[Effects of calcium antagonists on atherosclerosis progression and intima media thickness] [2000]

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. [1999.11.20]

The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. [1999.05]

Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. [1998.10]

Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. [1998.05]

Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. [1998.03]

Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. [1998.03]

New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. [1998]

Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. [1997.12]

Salt and blood pressure responses to calcium antagonism in hypertensive patients. [1997.09]

Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. [1997.05]

Other research related to Dynacirc CR (Isradipine)

Pharmacokinetic properties of isradipine after single-dose and multiple-dose oral administration in Chinese volunteers: a randomized, open-label, parallel-group phase I study. [2013]

Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion. [2013]

A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. [2011.09]

L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. [2011.01]

Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. [2010.12.15]

Isradipine for treatment of acute hypertension in hospitalized children and adolescents. [2010.11]

Transdermal therapeutic system of isradipine: effect of hydrophilic and hydrophobic matrix on in vitro and ex vivo characteristics. [2010.07]

Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: Complementary roles of L-type calcium channel and NMDA receptors. [2009.05]

Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine. [2008]

Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. [2006.07]

Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts. [2006.03.27]

Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. [2005.04]

A multicenter study using causal readings, self-recordings, and ambulatory blood pressure monitoring to assess isradipine effects. AMICUS Study Group. [1994.07]

Other possibly related research studies

A review of calcium channel antagonists in the treatment of pediatric hypertension. [2006]

Antihypertensive pharmacobezoar. [2006.04]

The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man. [2006.09]

Dose- and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects. [2007]

Chronotherapy With Nifedipine GITS in Hypertensive Patients: Improved Efficacy and Safety With Bedtime Dosing. [2008.08]

Time-dependent up-regulation of Ca(2+) channels in vas deferens of newborn rats fed with breast milk of mothers under treatment with nifedipine. [2008.12.03]

Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat. [2008.11]

Hypertensive emergency successfully treated with metoprolol: a case report. [2009.05]

Evaluation of the tablet core factors influencing the release kinetics and the loadability of push-pull osmotic systems. [2009.04]

Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. [2009.03.15]

Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. [2010.09]

A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. [2010]

Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. [2011.11.09]

The role of calcium channel blockers and resveratrol in the prevention of paraquat-induced parkinsonism in Drosophila melanogaster: a locomotor analysis. [2011.06]

Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. [2011]

Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure. [2013]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017